First Patient Dosed in Allogene’s ALLO-715 + Nirogacestat Cohort in the Ph1 UNIVERSAL Trial
On Monday, April 12, Allogene and SpringWorks announced (press release) that the first patient has been dosed with ALLO-715 (BCMA CAR-T) + nirogacestat (GSI) in the Ph1 UNIVERSAL trial (r/r MM). Below, Celltelligence provides insights into Allogene’s and key competitor Precision Biosciences’s clinical progress combining a GSI with their lead BCMA CAR-T assets, while discussing other strategies currently under evaluation to improve BCMA-targeting CAR-T efficacy.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.